AnalystsSean Lee
Sean Lee's Stock Forecasts

Analyst Ranking
Top 24%
#1234 out of 5192 analysts
Average Return
+5.1%
Win Rate
30%33 out of 110
Risk vs Reward
Poor
Good

Sean Lee's 5 best and worst ratings

Name / TickerGain/LossEntry PriceExit PricePeriodRating
Monopar TherapeuticsMNPR
+1,072.87%$3.36$39.42
2024-05-09 -
2025-05-09
Buy
Corvus Pharmaceuticals IncCRVS
+457.01%$3.35$18.66
2025-03-25 -
2026-02-13
Buy
Monopar TherapeuticsMNPR
+398.68%$16.66$83.08
2024-11-10 -
2025-11-10
Buy
Alphatec Holdings IncATEC
+346.70%$3.94$17.60
2020-04-08 -
2021-04-09
Buy
Verastem IncVSTM
+231.90%$2.32$7.70
2024-08-11 -
2025-08-11
Buy

Sean Lee's Stock Coverage

Name / TickerNo. RatingsRatingPrice TargetUpside/DownsideActionDate
Dogwood Therapeutics IncDWTX
6Buy$12.00+290.88%Reiterates
15 days ago
Kazia Therapeutics LtdKZIA
7Buy$18.00+259.28%Reiterates
17 days ago
Plus Therapeutics IncPSTV
14Buy$1.00+257.14%Maintains
22 days ago
Corvus Pharmaceuticals IncCRVS
4Buy$27.00+44.69%Maintains
25 days ago
Alphatec Holdings IncATEC
13Buy$24.00+79.64%Reiterates
a month ago
Cytosorbents CorpCTSO
14Hold$0.75+17.00%Maintains
3 months ago
Senseonics Holdings IncSENS
3Buy$18.50+146.34%Maintains
3 months ago
Novavax IncNVAX
2Buy$11.00+26.44%Maintains
4 months ago
Akari Therapeutics PLCAKTX
2Buy$1.60+586.70%Reiterates
5 months ago
Casi Pharmaceuticals IncCASI
10Buy$4.00+370.59%Reiterates
5 months ago
Myomo IncMYO
6Buy$5.00+509.76%Maintains
6 months ago
Verastem IncVSTM
14Buy$14.00+140.55%Maintains
9 months ago
Monopar TherapeuticsMNPR
9Buy$40.00-27.88%Reiterates
10 months ago
Gritstone Bio IncGRTSQ
12Hold$0.50N/ADowngrades
a year ago
Thermogenesis Holdings IncTHMO
6Buy$5.00N/AReiterates
2 years ago
Aceragen IncACGN
1HoldN/AN/ADowngrades
5 years ago
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.